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Improving testing for hepatitis B before treatment
with rituximab
Jessica K. Dysona,d, Laura Jopsona, Sarah Nga, Matthew Loweryb, Jayne Harwoodc, Sheila Waughc,
Manoj Valappilc,f and Stuart McPhersona,e
Aims/Objectives/Background Individuals with current or previous infection with the hepatitis B virus (HBV) can experience
viral reactivation when treated with immunosuppression. Rituximab, an anti-CD20 antibody used to treat many diseases, has
potent immunosuppressant effects with a high risk of causing HBV reactivation. Reactivation can range from elevated liver
enzymes to acute severe hepatitis with liver failure and a significant mortality risk. HBV screening and appropriate use of
prophylactic antiviral therapy can prevent reactivation. This work describes the introduction of a local policy for HBV testing in
patients before rituximab treatment and assesses its impact.
Methods and Results A baseline review (before policy introduction) of 90 patients showed that only 21 (23%) had hepatitis B
surface antigen (HBsAg) and 17 (19%) had hepatitis B core antibody (anti-HBcAb) tested before receiving rituximab. Following
introduction of the policy (on the basis of international guidelines), improved laboratory reporting protocols and targeted
education sessions, two further reviews of HBV testing rates among patients being initiated onto rituximab were performed. There
was a marked increase in pre-rituximab testing for HBsAg from 23 to 79% and for anti-HBcAb from 19 to 78%. Throughout the
study period, a total of one (0.8%) HBsAg-positive and six (4.7%) anti-HBcAb-positive patients were identified.
Conclusions This work clearly indicates that simple strategies can markedly improve appropriate HBV screening. In our cohort,
6% (of whom only 43% had recognized HBV risk factors) required antiviral prophylaxis, which emphasizes the importance of
universal screening before rituximab. Reinforcement of the guidelines and ongoing education is needed to further increase
testing rates. Eur J Gastroenterol Hepatol 28:1172–1178
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
It is estimated that globally, 240 million individuals are
chronically infected with the hepatitis B virus (HBV) and
two billion individuals have evidence of previous infection
[1,2]. Chronic infection with HBV (cHBV) causes hepati-
tis, which can progress to cirrhosis, liver failure and
hepatocellular carcinoma. The prevalence of cHBV varies
widely across the world, with areas such as Asia and
Africa being highly endemic [>8% hepatitis B surface
antigen (HBsAg) seropositive] [3]. Although, overall, the
UK is a low-endemicity area, rates of cHBV are higher in
individuals who have migrated from endemic countries [4].
A previous community screening study from the North-
East of England found that 8.7% of the British-Chinese
population and 3.1% of individuals born in Pakistan were
chronically infected with HBV, and the majority did not
know that they were infected [5].
It is well known that individuals with cHBV or past
infection with HBV can experience a reactivation of the
virus when treated with immunosuppressive therapy [6,7].
As a result, screening for HBV [HBsAg and hepatitis B core
antibody (anti-HBcAb) testing] has been recommended for
all patients receiving immunosuppression or chemotherapy
by the Centers for Disease Control and Prevention (CDC)
since 2008 [8], but this has not been adopted widely
[9,10]. It is well recognized that screening for HBV
remains variable, with a large US series showing that only
16% of patients were screened before receiving che-
motherapy [11]. Interestingly, the latest guidance from the
American Gastroenterological Association (AGA) does not
recommend testing for HBV in all patients receiving che-
motherapy, although they do specifically recommend
testing in patients before treatment with rituximab [12].
Rituximab is a chimeric monoclonal antibody against
the protein CD20, which is primarily found on the surface
of B cells. It has potent immunosuppressant effects and is
now used to treat many diseases including haematological
malignancies, rheumatological conditions and other auto-
immune disorders. Because of its particularly potent
immunosuppressive effects, 67–85% of HBsAg-positive
patients not on antiviral therapy who are treated with
rituximab will experience a flare of hepatitis [13,14] and
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up to 25% of patients with past infection (anti-HBcAb
positive, HBsAg negative) will have reactivation of HBV
[15,16]. HBV reactivation can range from a subclinical
increase in HBV DNA levels, to elevated liver enzymes, to
acute severe hepatitis with liver failure and a significant
risk of death (ranging from 4 to 60%) [14,17,18]. Because
of its particularly high risk of causing reactivation of HBV,
the Food and Drug Administration (FDA) issued specific
guidance in September 2013 specifically recommending
that patients treated with rituximab are screened for
HBsAg and anti-HBcAb before the initiation of treatment
[19]. Importantly, reactivation of HBV can be prevented
by the use of prophylactic antiviral therapy, which has
been shown to almost eliminate the risk of HBV reacti-
vation [20–22]. In the UK, the National Institute for
Health and Care Clinical Excellence (NICE) advises that
all HBsAg-positive or anti-HBcAb-positive patients receive
prophylactic antiviral therapy to prevent reactivation [6].
The risks associated with reactivation of HBV with
rituximab treatment were highlighted in our own unit
recently when an anti-HBcAb-positive, HBsAg-negative
patient with diffuse large B-cell lymphoma developed severe
fibrosing cholestatic hepatitis secondary to HBV reactivation
with rituximab (as part of the R-CHOP regimen) that
required a prolonged hospital admission despite initiation of
antiviral therapy [23]. The aim of this work is to describe the
introduction of a hospital-wide policy on HBV testing in
patients before treatment with rituximab and to assess its
impact.
Materials and methods
Collection of baseline rates of testing for hepatitis B virus
before initiation of the policy
An initial retrospective review was performed of HBV
testing in adult patients receiving rituximab for the first
time in the Newcastle upon Tyne Hospitals NHS
Foundation Trust between September and December 2012
(4 months). The review was registered and approved by
the Hospital Clinical Governance Department. The
patients were identified from Pharmacy records as all
rituximab was dispensed by the hospital pharmacy.
Paediatric patients, patients with a bone marrow or solid
organ transplant and those receiving rituximab as part of a
clinical trial were excluded as they have HBV testing as
part of their treatment protocol. Clinical details were col-
lected from electronic health records including the
following:
(1) Demographic information.
(2) Indication for rituximab.
(3) Details of coprescribed immunosuppressants/
chemotherapy.
(4) Whether HBsAg and anti-HBcAb tests were per-
formed before rituximab administration (within pre-
vious 1 year).
(5) Results of HBV testing.
(6) Risk factors for infection if HBsAg or anti-HBcAb
positive.
(7) Use of prophylactic antivirals.
(8) Patient outcomes.
Development and introduction of a hospital-wide policy
on hepatitis B virus testing before immunosuppression/
chemotherapy
In January 2013, a hospital policy was introduced on the
basis of the European Association of the Study of the Liver
(EASL) guidelines [7] that recommended that all patients
who were commencing chemotherapy or long-term
immunosuppression should be screened for evidence of
current or past HBV infection. To help ensure that the
pathway was adhered to, additional laboratory reporting
protocols were put in place.
Laboratory testing and reporting
All samples submitted for preimmunosuppression HBV
testing were screened for HBsAg and total HBcAb using
Elecsys HBsAg II and Elecsys anti-HBc Assay (Roche
Diagnostics Ltd, Burgess Hill, United Kingdom).
Laboratory protocols were designed for additional testing,
interpretation and reporting of preimmunosuppression
HBV screening samples yielding a reactive result.
Hepatitis B surface antigen-reactive samples
Other HBV markers including HB core IgM, HB e antigen
and anti-HB e antibody were tested and results were
interpreted and reported with appropriate comments
according to the Laboratory Standard Operating
Procedure in line with the recommended Standard for
Microbiology Investigation methods [24]. An additional
report comment for urgent referral to Hepatology was
added. Results were telephoned to the requesting clinician
and a repeat sample was requested to confirm HBV status
and check the HBV viral load level.
Antihepatitis B virus core-positive (hepatitis B surface
antigen-negative) samples
Additional testing for anti-HBsAb was performed, and
where anti-HBs was not detected at a level greater than
10 IU/l, the presence of anti-HBV core antibodies was
confirmed using a second assay [24]. Results were com-
municated to the requesting clinician either by telephone
or by a secure e-mail, and a report was issued with the
comment: ‘Evidence of past, resolved hepatitis B virus
infection. Potential for HBV reactivation associated with
immunosuppressive therapy. Recommend referral to viral
hepatology services’.
Where the presence of anti-HBc could not be confirmed,
including testing of a repeat sample, the result was
reported as indeterminate and where the index of suspi-
cion of past HBV infection was very low, results were
considered to be nonspecific and clinicians were advised to
check for HBV markers if liver function tests became ele-
vated during immunosuppression.
In some cases of positive and indeterminate anti-HBc
results, it is deemed likely that the result was because of
passively acquired antibodies from recently received blood
products. Where possible, this is confirmed by testing of
earlier and later samples. The pathway for managing
patients with positive HBV serology is shown in Fig. 1.
The guideline was published on the hospital guidelines
website and all hospital clinicians were advised of the
policy by e-mail. In addition, six 30-min education sessions
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were conducted for clinical teams (consultants, junior
doctors, nurse specialists and pharmacists) who regularly
prescribe chemotherapy or immunosuppression, which
specifically included all the major rituximab prescribers.
Education sessions were a PowerPoint presentation deliv-
ered by S.M. or J.D. describing a case of HBV reactivation
following rituximab therapy, explaining the clinical
implications of HBV and summarizing the evidence on
reactivation and rituximab use. A simple referral proforma
for HBsAg-positive and anti-HBcAb-positive patients was
developed to ease the process of referral to the viral
hepatitis service.
Review of hepatitis B virus testing rates following the
introduction of the policy
Two further retrospective reviews of HBV testing rates
among patients being initiated onto rituximab were per-
formed after the introduction of the HBV testing policy to
assess its impact. These were performed between February
and April 2014 (3 months) and September and December
2014 (4 months), and followed the same methodology as
the original audit. No further specific education sessions
were conducted between the two postpolicy assessment
periods. However, the policy was reinforced with feedback
from subsequent audit results and contacts between the
virology and the clinical teams with positive results.
Definition of hepatitis B virus reactivation
HBV reactivation was defined as any of the following:
(1) Reappearance of HBV DNA and/or HBsAg in
previously anti-HBcAb-positive individuals.
(2) Increase in HBV DNA of more than 1 log IU/ml with
or without increase in alanine aminotransferase levels
in an HBsAg-positive patient.
Results
Baseline demographics and hepatitis B virus testing rates
in the original cohort
A total of 90 patients were initiated on rituximab between
September and December 2012 (4 months). The median
age of the patients was 62 years (range: 18–88 years) and
60 (67%) were women. The main rituximab prescribing
specialties were rheumatology (56%) and haematology
(32%). Rituximab was used with other immunosuppres-
sion in 45%, alone in 29% and with other chemotherapy
in 26% of patients (Fig. 2).
Overall, only 21 (23%) patients had HBsAg and 17
(19%) patients had anti-HBcAb tested before treatment with
rituximab. Two patients were anti-HBcAb positive, but none
were HBsAg positive. Both anti-HBcAb patients were HBV
DNA negative and neither were administered prophylactic
antiviral therapy. One anti-HBcAb-positive patient (HBsAg
and anti-HBsAb negative with an undetectable HBV DNA)
developed a significant reactivation of HBV with jaundice.
He required admission to hospital and was treated with
tenofovir, and the jaundice resolved after 8 weeks.
This review highlighted poor compliance with interna-
tional recommendations for HBV testing before initiation
of immunosuppression. As a result, a hospital-wide
guideline was developed (Fig. 1) and targeted education
sessions were delivered to all the teams that treat patients
with rituximab.
High risk (e.g. rituximab, BMT, stem
cell transplant, chemotherapy, solid
organ transplant)
Low risk ( e.g. long course steroids,
thiopurines, methotrexate, anti-TNFs)
Check HBV DNA + LFTs
Refer hepatology
cAb positive only
Antiviral therapy with
tenofovir or entecavir
Start lamivudine
Monitor LFTs until
≥6 months after
therapy stopped
Undetectable DNA
Normal LFTs
cAb positive only
Undetectable DNA
Normal LFTs
Consider antiviral
prophylaxis with
lamivudine if very high
risk (e.g rituximab)
Monitor LFTs + HBsAg (4
weekly) + HBV DNA (12
weekly)
Check HBV DNA + LFTs
Refer hepatology
Detectable DNA
+/− abnormal LFTs
sAg positive
Low risk
Monitor HBsAg
+ HBV DNA +
LFTs 3 monthly
Hepatology
review − likely
need antiviral
therapy
sAg positive
sAg positive
and/or
cAb positive
sAg positive
and/or
cAb positive
Fig. 1. Algorithm for prevention of HBV reactivation in patients undergoing immunosuppression. BMT, bone marrow transplant; cAb, core antibody; HBsAg,
hepatitis B surface antigen; HBV, hepatitis B virus; IBD, inflammatory bowel disease; LFTs, liver function tests; sAg, surface antigen; TNF, tumour necrosis
factor.
1174 European Journal of Gastroenterology & Hepatology October 2016 •Volume 28 •Number 10
Hepatitis B virus testing rates after the introduction of a
hepatitis B virus testing policy
Table 1 shows a comparison of the testing rates before and
after the introduction of a policy on testing for HBV in all
patients before initiation of rituximab. Overall, there was a
marked increase in prerituximab testing for HBsAg from
23 to 79%. Testing rates for anti-HBcAb also increased
considerably from 19 to 78%.
Prescription of prophylactic antiviral therapy for hepatitis
B surface antigen-positive and antihepatitis B core
antibody-positive individuals
Throughout the entire study period, a total of one (0.8%)
HBsAg-positive and six (4.7%) anti-HBcAb patients were
identified. According to the NICE guidelines that were
issued in 2013, it was recommended that all these patients
should receive prophylactic antiviral therapy to prevent
reactivation. Neither of the two anti-HBcAb-positive
patients identified in the original cohort were treated
with prophylactic antivirals as this was just before the
publication of NICE guidelines. Of the five HBsAg-positive
or anti-HBcAb-positive patients identified after the policy
introduction, three received antiviral therapy before
receiving rituximab. The HBsAg-positive patient was
already on treatment with entecavir with an undetectable
HBV DNA. Two of the anti-HBcAb-positive patients were
commenced on lamivudine prophylactically. On further
investigation, both patients who did not receive antiviral
therapy were anti-HBcAb positive only with undetectable
HBV DNA. One of these patients had received high-
dose intravenous immunoglobulin for low-grade
Waldenstrom’s macroglobulinaemia and was believed to
have passively acquired the anti-HBcAb. Repeat testing
3 weeks later showed decreasing levels of anti-HBcAb
consistent with this hypothesis. The other patient was
noted to be anti-HBcAb positive after four cycles of
rituximab and was commenced on lamivudine at that
stage. His rituximab was suspended until it had been
confirmed that the HBV DNA PCR was undetectable.
Of the seven patients in our total cohort who tested
positive for HBsAg or anti-HBcAb, four (57%) had no
obvious risk factors for hepatitis B infection. The other
three patients were at risk because of their ethnicity; they
were from Egypt, Pakistan and China.
Discussion
It is well recognized that treatment with immunosuppres-
sive therapy can reactivate HBV in patients with current or
previous infection. Reactivation of HBV can have sig-
nificant clinical consequences including liver failure, which
carries a high mortality rate [14,17,18,25,26]. The risk of
HBV reactivation associated with rituximab, a very potent
immunosuppressant, is particularly high, occurring in
67–85% of untreated HBsAg-positive individuals and up
to 25% of anti-HBcAb patients. Prophylactic treatment
with oral antivirals, such as lamivudine and entecavir, has
been shown to prevent viral reactivation [20–22,27,28].
As a result, guidelines recommend screening for HBV with
HBsAg and anti-HBcAb in all patients before the initiation
of rituximab and, if either is detectable, then antiviral
prophylaxis is recommended to reduce the risk of reacti-
vation [6,7,12,19].
The initial aim of this project was to review practice in
our hospital and determine the proportion of patients who
had appropriate HBV testing before the initiation of
rituximab, and if necessary, implement measures to
improve testing and prophylaxis rates to improve patient
safety. Disappointingly, our baseline assessment of HBV
R-CHOP
Rituximab alone
Rituximab + other
chemotherapy
Rituximab + other
immunosuppression
10%
34%
29%
27%
Fig. 2. Prescription of rituximab.
Table 1. Hepatitis B virus testing practice across three time periods
Prepolicy September–December 2012
(n=90)
Postpolicy February–April 2014
(n=91)
Postpolicy September–December 2014
(n=67)
Sex (male) [n (%)] 30 (33) 46 (51) 31 (46)
Median age (range) (years) 62 (18–88) 65 (21–92) 64 (22–89)
HBsAg tested [n (%)] 21 (23) 59 (65) 53 (79)
HBcAb tested [n (%)] 17 (19) 59 (65) 52 (78)
HBsAg+ [n (%)] 0 0 1 (1)
HBcAb+ [n (%)] 2 (12) 0 4 (6)
HBV DNA detected if HBcAb+ 0 NA 1/4 (25)
ALT>40 IU/ml in patients with no
serology checked [n (%)]
4/65 (6) 3 (9) 0
ALT, alanine aminotransferase; HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
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testing indicated low rates of HBV screening (23% HBsAg
and 19% anti-HBcAb), suggesting the need to implement a
change to improve practice. The results of our baseline
assessment were in agreement with previous studies carried
out elsewhere, where appropriate HBV testing rates ran-
ged from 14 to 32% [9–11,27]. Although we did not
formally assess the reasons for the low rates of HBV
testing, discussion with clinicians indicated that there was
a general lack of awareness of the risks of HBV reactiva-
tion with rituximab and few clinicians had ever encoun-
tered a case; thus, they did not perceive it as a problem.
In an attempt to improve HBV testing rates and initia-
tion of appropriate antiviral prophylaxis in patients
undergoing immunosuppression or chemotherapy, a hos-
pital guideline (Fig. 1) was developed on the basis of
international recommendations [7], which was dis-
seminated to all clinicians. In addition, six 30-min educa-
tion sessions were delivered to staff involved in the
management of patients on immunosuppression or che-
motherapy. Each session included a case example of an
HBsAg-negative/anti-HBcAb-positive patient with lym-
phoma who developed liver failure secondary to HBV
reactivation on R-CHOP chemotherapy [23], followed by
the rationale for HBV testing and prophylaxis. Following
the introduction of this hospital guideline, there was a
marked increase in appropriate HBV screening in patients
before receiving rituximab from 19 to 78%. The improved
screening rates in our Trust now exceed those reported by
the American Society of Clinical Oncology (ASCO)
Quality Oncology Practice Initiative (QOPI) [29], which
successfully screened nearly 70% of patients with non-
Hodgkin lymphoma before the initiation of rituximab.
QOPI was created in 2002 to measure quality and enable
quality improvement in cancer care. Ongoing work is
needed to further improve testing rates in our hospital as
one in five patients treated with rituximab remains untes-
ted for HBV. Alternative methods of improving HBV
testing rates could include the use of a computer-assisted
hospital-based screening reminder system, which was
shown to achieve an HBsAg screening rate of 85.5% [29].
However, that method was still associated with a dis-
appointing rate of appropriate antiviral prophylaxis of
only 45.5% [30].
Some clinicians cite the low prevalence of HBV in some
areas as a reason not to offer universal HBV screening
before immunosuppression/chemotherapy, and instead
target individuals with associated risk factors (such as
country of birth, injecting drug use, sexual contact, etc.) or
do not screen at all [11]. Importantly, in this study, even in
a low HBV prevalence country (0.5% HBsAg ser-
opositivity), there was a high rate of HBsAg and anti-
HBcAb positivity (6%), which suggests that screening in
patients receiving rituximab is worthwhile as all these
patients would be offered prophylactic antiviral therapy. A
previous study showed that only 60% of patients with
HBV infection have obvious risk factors for the infection,
which means that targeting risk factors will miss a sig-
nificant proportion of cases [31]. This was mirrored in the
present study, where 57% of the patients who tested
positive did not have any obvious risk factors for HBV,
which reinforces the need for universal testing. Screening
all patients for HBV who are receiving rituximab-based
chemotherapy has also been shown to be more cost
effective than screening ‘high-risk’ individuals or not
screening at all [32].
It is increasingly being recognized that individuals with
past infection (anti-HBcAb positive) have a significant risk of
HBV reactivation with rituximab (up to 25%), which is
higher than that for other immunosuppressants (5%) [33,34].
HBV incorporates covalently closed circular HBV DNA
(cccDNA) in hepatocyte nuclei, which remains present even
after the immune control of the infection, with subsequent
disappearance of circulating HBsAg from the peripheral
blood [35]. If patients are immunosuppressed with drugs,
such as rituximab, HBV viral replication can be reinitiated,
leading to reactivation. Patients who develop HBV reactiva-
tion following treatment with rituximab have a 20–50% risk
of mortality [34,36–38], which appears to be higher than that
found with other immunosuppressants. The mechanisms
leading to HBV reactivation with rituximab remain to be
elucidated, but may be more complex than B-cell depletion
alone [39]. Various hypotheses have been suggested including
changes in T lymphocyte activity and number [40], and
reduction of anti-HBV antibodies [41]. It is interesting to note
that HBV reactivation in patients receiving BCR-ABL tyrosine
kinase inhibitors has recently been recognized. The European
Medicines Agency (EMA) now advises testing for HBV before
initiating treatment with these agents (e.g. imatinib, dasatinib,
nilotinib) [42].
There is convincing evidence that preemptive antiviral
prophylaxis is more effective than treating patients once
their HBV DNA starts to increase, both in terms of pre-
venting liver injury and reducing mortality [27,28]. Huang
et al. [20] compared the use of prophylactic entecavir
before rituximab-based chemotherapy to therapeutic
entecavir (at the time of HBV reactivation and HBsAg
reverse seroconversion since chemotherapy). The cumula-
tive HBV reactivation rates at months 6, 12 and 18 after
chemotherapy were 8, 11.2 and 25.9%, respectively, in the
control group and 0, 0 and 4.3% in the entecavir pro-
phylactic group (P=0.019). A recent randomized, open-
label, phase 3 study from China [22] compared entecavir
with lamivudine for the treatment of HBsAg-positive
patients with low viral loads receiving R-CHOP. The
results showed significantly lower rates of HBV-related
hepatitis, HBV reactivation and chemotherapy disruption
in the entecavir group. There was no significant difference
between treatment-related adverse events between the two
groups. Both the EASL and NICE guidance provide clear
advice on the use of prophylactic antivirals for all HBsAg-
positive patients receiving immunosuppression of che-
motherapy [6,7].
It is important that HBV screening be performed before
starting any immunosuppression to avoid false-negative
HB core results because of immunosuppression, ideally at
the time of the diagnosis of conditions requiring immu-
nosuppression. Although the HB core-positive (HBsAg
negative) profile reflects past HBV infection, it could also
reflect passively acquired antibody from recent blood
products or may rarely be because of nonspecific reactivity
or HBsAg mutants. Additional testing is critical to clarify
the true HBV status to avoid unnecessary antiviral pro-
phylaxis. As the frequency of HBV testing increases in
patients receiving immunosuppression/chemotherapy,
there is likely to be an associated increase in false-positive
results, as observed in our cohort with the patient who
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received intravenous immunoglobulin. This means that
there needs to be close collaboration between virology and
clinical teams to ensure that all test results are interpreted
accurately.
There are limitations with this study. The national
guidelines were in evolution during the study period and
some of the improvement in screening practices may be
because of the dissemination of the NICE guidelines and FDA
guidance as well as our implementation methods. In addition,
the reasons for the low rates of HBV screening before
implementation of the policy were not formally assessed.
This work clearly shows that simple strategies (intro-
duction of a local guideline, targeted education and close
liaison with the virologists) can markedly improve appro-
priate HBV screening. In our cohort, 6% of patients (of
whom only 43% had recognized risk factors for HBV)
required antiviral prophylaxis, which emphasizes the
importance of universal screening in patients before ritux-
imab. However, reinforcement of the guidelines and ongo-
ing education is needed to further increase testing rates.
Education should be across the broader medical audience,
but with specifically targeted sessions to specialities who are
known to be users of rituximab. Screening for HBV in
patients receiving rituximab is now clearly defined, but the
magnitude of the risk associated with other chemother-
apeutic and immunosuppressive regimens is more con-
troversial [43] and further work is needed to define this.
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